



## Andersen-Tawil Syndrome

Synonym: Long QT Syndrome Type 7 (LQTS Type 7)

Aravindhan Veerapandiyan, MBBS,<sup>1</sup> Jeffrey M Statland, MD,<sup>2</sup> and Rabi Tawil, MD<sup>1</sup>

Created: November 22, 2004; Updated: June 7, 2018.

### Summary

#### Clinical characteristics

Andersen-Tawil syndrome (ATS) is characterized by a triad of: episodic flaccid muscle weakness (i.e., periodic paralysis); ventricular arrhythmias and prolonged QT interval; and anomalies including low-set ears, widely spaced eyes, small mandible, fifth-digit clinodactyly, syndactyly, short stature, and scoliosis. Affected individuals present in the first or second decade with either cardiac symptoms (palpitations and/or syncope) or weakness that occurs spontaneously following prolonged rest or following rest after exertion. Mild permanent weakness is common. Mild learning difficulties and a distinct neurocognitive phenotype (i.e., deficits in executive function and abstract reasoning) have been described.

#### Diagnosis/testing

The diagnosis of ATS is established in an individual with characteristic clinical and EKG findings and/or identification of a pathogenic variant in *KCNJ2*.

#### Management

*Treatment of manifestations:* For episodic weakness: if serum potassium concentration is low (<3.0 mmol/L), administration of oral potassium (20-30 mEq/L) every 15-30 minutes (not to exceed 200 mEq in a 12-hour period) until the serum concentration normalizes; if a relative drop in serum potassium within the normal range causes episodic paralysis, an individual potassium replacement regimen with a goal of maintaining serum potassium levels in the high range of normal can be considered; if serum potassium concentration is high, ingesting carbohydrates may lower serum potassium levels. Mild exercise may shorten or reduce the severity of the attack.

*Prevention of primary manifestations:* Reduction in frequency and severity of episodic attacks of weakness with lifestyle/dietary modification to avoid known triggers; use of carbonic anhydrase inhibitors; daily use of slow-release potassium supplements; implantable cardioverter-defibrillator for those with tachycardia-induced

**Author Affiliations:** 1 Department of Neurology, University of Rochester Medical Center, Rochester, New York; Email: aravindhan\_veerapandiyan@urmc.rochester.edu; Email: rabi\_tawil@urmc.rochester.edu. 2 Department of Neurology, University of Kansas Medical Center, Kansas City, Kansas; Email: jstatland@kumc.edu.

syncope. Empiric treatment with flecainide should be considered for significant, frequent ventricular arrhythmias in the setting of reduced left ventricular function.

*Prevention of secondary complications:* Cautious use of antiarrhythmic drugs (particularly class I drugs) that may paradoxically exacerbate the neuromuscular symptoms.

*Surveillance:* Annual screening of asymptomatic individuals with a *KCNJ2* pathogenic variant with a 12-lead EKG and 24-hour Holter monitoring.

*Agents/circumstances to avoid:* Medications known to prolong QT intervals; salbutamol inhalers (may exacerbate cardiac arrhythmias); thiazide and other potassium-wasting diuretics (may provoke drug-induced hypokalemia and could aggravate the QT interval prolongation).

*Evaluation of relatives at risk:* Molecular genetic testing if the pathogenic variant is known; if not, detailed neurologic and cardiologic evaluation, 12-lead EKG, and 24-hour Holter monitoring to reduce morbidity and mortality through early diagnosis and treatment of at-risk relatives.

## Genetic counseling

ATS is inherited in an autosomal dominant manner. At least 50% of individuals diagnosed with ATS have an affected parent. Up to 50% of affected individuals have ATS as the result of a *de novo* pathogenic variant. Each child of an individual with ATS has a 50% chance of inheriting the disorder. Prenatal diagnosis for pregnancies at increased risk is possible if the *KCNJ2* pathogenic variant has been identified in an affected family member.

## Diagnosis

### Suggestive Findings

Andersen-Tawil syndrome (ATS) **should be suspected** in individuals with **either A or B**:

A. Presence of two of the following three criteria:

- Periodic paralysis
- Symptomatic cardiac arrhythmias or electrocardiographic evidence of enlarged U-waves, ventricular ectopy, or a prolonged QTc or QUc interval
- Characteristic facies, dental anomalies, small hands and feet, AND at least two of the following:
  - Low-set ears
  - Widely spaced eyes
  - Small mandible
  - Fifth-digit clinodactyly
  - Syndactyly of toes 2 and 3

B. One of the above three criteria AND at least one other family member who meets two of the three criteria [Statland et al 2018]

### Supportive Findings

Individuals with either episodic weakness or cardiac symptoms require careful evaluation by a neurologist and/or cardiologist as well as measurement of serum potassium concentration (baseline and during attacks of flaccid paralysis), a 12-lead EKG, a 24-hour Holter monitor, and possibly the long exercise protocol.

- **Serum potassium concentration** during episodes of weakness may be elevated, normal, or, most commonly, reduced (<3.5 mmol/U) [Sansone & Tawil 2007, Statland et al 2018].

- **Routine nerve conduction electrophysiology** is normal between episodes. A more sensitive electrophysiologic study, the long exercise protocol, may reveal an immediate post-exercise increment followed by an abnormal decrement in the compound motor action potential amplitude (>40%) [Katz et al 1999] or area (>50%) 20-40 minutes post exercise [Kuntzer et al 2000, Fournier et al 2004]. In a study of 11 individuals with ATS, 82% met long-exercise amplitude decrement criteria for abnormal testing [Tan et al 2011].
- **Electrocardiogram** may reveal characteristic abnormalities including prominent U waves, prolonged Q-U intervals, premature ventricular contractions, polymorphic ventricular tachycardia, and bidirectional ventricular tachycardia [Zhang et al 2005, Delannoy et al 2013, Koppikar et al 2015, Statland et al 2018].
- **24-hour Holter monitoring** is important to document the presence, frequency, and duration of ventricular tachycardia (VT) and the presence or absence of associated symptoms.

## Establishing the Diagnosis

The diagnosis of ATS is **established** in a proband with the presence of A or B in Suggestive Findings and/or by identification of a heterozygous pathogenic variant in *KCNJ2* by molecular genetic testing (see Table 1).

Molecular genetic testing approaches can include a combination of **gene-targeted testing** (single-gene testing, multigene panel) and **comprehensive genomic testing** (exome sequencing, genome sequencing) depending on the phenotype.

Gene-targeted testing requires that the clinician determine which gene(s) are likely involved, whereas genomic testing does not. Because the phenotype of ATS is broad, individuals with the distinctive findings described in Suggestive Findings are likely to be diagnosed using gene-targeted testing (see Option 1), whereas those with a phenotype indistinguishable from many other inherited disorders with cardiac arrhythmias are more likely to be diagnosed using genomic testing (see Option 2).

### Option 1

When the phenotypic and laboratory findings suggest the diagnosis of ATS molecular genetic testing approaches can include **serial single-gene testing** or use of a **multigene panel**:

- **Serial single-gene testing.** Sequence analysis detects small intragenic deletions/insertions and missense, nonsense, and splice site variants; typically, exon or whole-gene deletions/duplications are not detected. Perform sequence analysis of *KCNJ2* first. If no pathogenic variant is found perform gene-targeted deletion/duplication analysis of *KCNJ2* to detect intragenic deletions or duplications. If no *KCNJ2* pathogenic variant is found, perform sequence analysis of *KCNJ5* (see Table 1, footnote 7).
- **A multigene panel** that includes *KCNJ2*, *KCNJ5*, and other genes of interest (see Differential Diagnosis and [Long QT Syndrome](#)) is most likely to identify the genetic cause of the condition at the most reasonable cost while limiting identification of variants of uncertain significance and pathogenic variants in genes that do not explain the underlying phenotype. Note: (1) The genes included in the panel and the diagnostic sensitivity of the testing used for each gene vary by laboratory and are likely to change over time. (2) Some multigene panels may include genes not associated with the condition discussed in this *GeneReview*. (3) In some laboratories, panel options may include a custom laboratory-designed panel and/or custom phenotype-focused exome analysis that includes genes specified by the clinician. (4) Methods used in a panel may include sequence analysis, deletion/duplication analysis, and/or other non-sequencing-based tests.

For an introduction to multigene panels click [here](#). More detailed information for clinicians ordering genetic tests can be found [here](#).

## Option 2

When the phenotype is indistinguishable from many other inherited disorders characterized by cardiac arrhythmias, **comprehensive genomic testing** (which does not require the clinician to determine which gene[s] are likely involved) is the best option. **Exome sequencing** is most commonly used; **genome sequencing** is also possible.

For an introduction to comprehensive genomic testing click [here](#). More detailed information for clinicians ordering genomic testing can be found [here](#).

**Table 1.** Molecular Genetic Testing Used in Andersen-Tawil Syndrome

Gene <sup>1</sup>	Method	Proportion of Probands with a Pathogenic Variant <sup>2</sup> Detectable by Method
<i>KCNJ2</i>	Sequence analysis <sup>3</sup>	~70% <sup>4</sup>
	Gene-targeted deletion/duplication analysis <sup>5</sup>	Unknown <sup>6</sup>
<i>KCNJ5</i>	Sequence analysis <sup>3</sup>	See footnote 7.
	Gene-targeted deletion/duplication analysis <sup>5</sup>	Unknown, none reported
Unknown		~30%

1. See Table A. Genes and Databases for chromosome locus and protein.

2. See Molecular Genetics for information on allelic variants detected in this gene.

3. Sequence analysis detects variants that are benign, likely benign, of uncertain significance, likely pathogenic, or pathogenic. Variants may include small intragenic deletions/insertions and missense, nonsense, and splice site variants; typically, exon or whole-gene deletions/duplications are not detected. For issues to consider in interpretation of sequence analysis results, click [here](#).

4. Plaster et al [2001], Ai et al [2002], Andelfinger et al [2002], Tristani-Firouzi et al [2002], Donaldson et al [2003], Hosaka et al [2003]

5. Gene-targeted deletion/duplication analysis detects intragenic deletions or duplications. Methods used may include quantitative PCR, long-range PCR, multiplex ligation-dependent probe amplification (MLPA), and a gene-targeted microarray designed to detect single-exon deletions or duplications.

6. Large deletions of *KCNJ2* are reported [Lestner et al 2012, Vergult et al 2012, Marquis-Nicholson et al 2014]. The prevalence of large deletions is unknown.

7. One individual with periodic paralysis, ventricular arrhythmias, no history of hypertension, and normal plasma aldosterone levels was found to have a p.Gly387Thr variant in *KCNJ5*. Of individuals with suspected ATS in whom a *KCNJ2* pathogenic variant was not identified, 1/21 had a p.Thr158Ala *KCNJ5* variant identified [Kokunai et al 2014].

## Clinical Characteristics

### Clinical Description

Andersen-Tawil syndrome (ATS) is characterized by a triad of features:

- Episodic flaccid muscle weakness (periodic paralysis)
- Cardiac abnormalities (ventricular arrhythmias, prolonged QTc or QUc intervals, and prominent U waves)
- Distinctive dysmorphic features

Affected individuals present initially with either periodic paralysis or cardiac symptoms (palpitations and/or syncope) in the first or second decade [Tawil et al 1994, Tristani-Firouzi et al 2002]; however, prospective standardized natural history data are not yet available. The phenotype is highly variable. The characteristic triad is present in 58%-78% of individuals with *KCNJ2* pathogenic variants [Statland et al 2018].

**Weakness.** Intermittent weakness occurs spontaneously, or alternatively may be triggered by prolonged rest or rest following exertion. The attack frequency, duration, and severity are variable between and within affected

individuals. Mild permanent weakness is common [Tristani-Firouzi et al 2002]. Affected individuals can develop fixed proximal weakness over time.

**Ventricular arrhythmias** including bidirectional ventricular tachycardia (VT), polymorphic VT, and multifocal premature ventricular contractions may be asymptomatic, or may manifest (most commonly) as palpitations. Less common symptomatic presentations include syncope, cardiac arrest, or sudden death [Andelfinger et al 2002, Tristani-Firouzi et al 2002, Donaldson et al 2003]. While the EKG may reveal a long QTc (LQT) interval, characteristic T-U patterns including enlarged U waves, a wide T-U junction, and prolonged terminal T-wave downslope distinguish ATS from other LQT syndromes [Zhang et al 2005, Haruna et al 2007]. A large case series found no significant difference in the incidence of ventricular tachyarrhythmias between individuals with typical and atypical presentations of ATS [Kimura et al 2012]. A retrospective multicenter French study of 36 individuals with ATS followed for an average of 9.5 years reported no deaths in follow up; four individuals experienced syncope and one individual had a non-fatal cardiac arrest [Delannoy et al 2013].

**Dilated cardiomyopathy** was observed in two of three affected individuals in a single kindred with pathogenic variant p.Arg218Trp [Schoonderwoerd et al 2006]. Additionally, cardiomyopathy was documented and reversed by treatment with flecainide in an individual with pathogenic variant p.Arg67Trp [Pellizzón et al 2008], and reversed by bisoprolol in another individual with typical clinical features of ATS and novel variant p.Leu222Ser [Rezazadeh et al 2016]. These reports suggest that dilated cardiomyopathy is a secondary phenotype as a consequence of chronic tachycardia rather than a primary phenotypic manifestation. Additional study is needed to further delineate this clinical feature.

**Distinctive physical features** recognized initially included low-set ears, widely spaced eyes, small mandible, fifth-digit clinodactyly, second and third toe syndactyly, short stature, broad nasal root, and scoliosis [Andersen et al 1971, Tristani-Firouzi et al 2002, Donaldson et al 2003]. Dental enamel discoloration was noted in two kindreds with the p.Gly300Asp and p.Arg218Trp pathogenic variants [Davies et al 2005].

Detailed, prospectively collected data in ten individuals with confirmed *KCNJ2* pathogenic variants have expanded the phenotype to include a characteristic facies and dental and skeletal anomalies [Yoon et al 2006a].

- Characteristic facies include broad forehead, short palpebral fissures, wide nasal bridge with bulbous nose, hypoplasia of maxilla and mandible, thin upper lip, and a triangular face.
- Dental findings include (among others) persistent primary dentition, multiple missing teeth (oligodontia), and dental crowding.
- Skeletal findings include mild syndactyly of toes two and three as well as fifth-digit clinodactyly.
- Novel findings include small hands and feet (<10th centile for age) and joint laxity.

Note: Isolated reports of **renal anomalies** include unilateral hypoplastic kidney [Andelfinger et al 2002] and renal tubular defect [Davies et al 2005].

**Mild learning difficulties** have been described [Davies et al 2005]. A distinct neurocognitive phenotype (i.e., deficits in executive function and abstract reasoning) has been recognized in individuals with a *KCNJ2* pathogenic variant despite IQ levels similar to those of their unaffected sibs [Yoon et al 2006b]. Growth restriction and developmental delay have been described as well [Kim et al 2016].

**Afebrile seizures** occurring only in infancy were reported in 4/23 (17%) of a Japanese cohort with molecularly confirmed ATS [Haruna et al 2007].

## Genotype-Phenotype Correlations

Whether a *KCNJ2* pathogenic variant is present or not, individuals with clinically defined ATS are phenotypically indistinguishable [Tristani-Firouzi et al 2002, Donaldson et al 2003].

In a case series that evaluated for *KCNJ2* pathogenic variants in individuals with typical (>2 ATS features) and atypical (only 1 ATS feature or catecholaminergic polymorphic ventricular tachycardia [CPVT]) features of ATS, the proportion of individuals with an identified pathogenic variant was 75% (15/20) in those with typical ATS, 71% (5/7) in those with the cardiac phenotype alone, 100% (2/2) in those with periodic paralysis, and 7% (2/28) in those with CPVT [Kimura et al 2012].

In a single large kindred with the *KCNJ2* p.Arg67Trp pathogenic variant, periodic paralysis was observed only in men, cardiac symptoms only in women, and congenital anomalies in both [Andelfinger et al 2002]. However, this apparent sex-limited bias in clinical presentation has not been confirmed [Donaldson et al 2003, Davies et al 2005].

A large five-generation family was found to have a deletion in *KCNJ2* (c.271\_282del12;p.Ala91\_Leu94del) and more severe cardiac manifestations, including 4/10 individuals receiving an implantable cardioverter-defibrillator and 5/10 reporting life-threatening ventricular arrhythmias in childhood [Fernlund et al 2013]. These individuals had characteristic mild dysmorphic features, but only one had periodic paralysis.

Two pathogenic variants in *KCNJ2* associated with a reduction in Kir2.1 current but without a dominant-negative effect on normal channels (p.Asn318Ser and p.Trp322Cys) were described in three individuals with an isolated cardiac phenotype: with premature ventricular contractions, ventricular tachycardia, or ventricular fibrillation [Limberg et al 2013].

A recent study examined the predictors of arrhythmias in 11 unrelated families with ATS (11 probands who were all female, 14 unaffected heterozygous family members with the *KCNJ2* pathogenic variant, and 19 family members without the pathogenic variant) and found that a higher risk for arrhythmia, syncope, and/or cardiac arrest was associated with the presence of micrognathia, periodic paralysis, and prolonged duration of the descending portion of T-wave ( $T_{\text{peak}} - T_{\text{end}}$  time). It was also noted that the ATS clinical manifestations appeared to be more severe in females. The presence of a benign / likely benign variant in *KCNH2* appeared to be associated with a higher risk for syncope [Krych et al 2017].

## Penetrance

Non-penetrance is evident in 6%-20% of individuals with an identifiable pathogenic variant [Andelfinger et al 2002, Tristani-Firouzi et al 2002, Donaldson et al 2003].

## Nomenclature

Although listed in OMIM, the following names for ATS are no longer in clinical use:

- Periodic paralysis, potassium-sensitive cardiodysrhythmic type
- Andersen cardiodysrhythmic periodic paralysis

## Prevalence

The prevalence of ATS is estimated at 0.08:100,000-0.1:100,000 [Horga et al 2013, Stunnenberg et al 2018].

## Genetically Related (Allelic) Disorders

**Familial atrial fibrillation 9** (OMIM 613980). A *KCNJ2* pathogenic missense variant was described in a Chinese family; five affected individuals and two individuals who did not have atrial fibrillation were identified to have the variant.



**Short QT syndrome 3** (OMIM 609622). A *KCNJ2* pathogenic missense variant was identified in a female age five years and her father who had short QT intervals and asymmetric T waves on EKG. Pathogenic variants in *KCNH2* and *KCNQ1*, the two genes associated with short QT syndrome, were not identified.

## Differential Diagnosis

Andersen-Tawil syndrome (ATS) should be considered in any individual presenting with periodic paralysis and ventricular arrhythmias or prominent U wave or prolonged QTc. Individuals with either episodic weakness or cardiac symptoms require careful evaluation by a neurologist and/or cardiologist as well as measurement of serum potassium concentration (baseline and during attacks of flaccid paralysis), a 12-lead EKG, a 24-hour Holter monitor, and possibly the long exercise protocol. The differential diagnosis depends on the initial presentation and includes the primary and secondary periodic paralyses, thyrotoxic periodic paralysis, and conditions associated with long QT.

## Episodes of Flaccid Paralysis

**Hypokalemic periodic paralysis** is the most common periodic paralysis. Affected individuals may experience paralytic episodes with concomitant hypokalemia (<2.5 mmol/L), and occasionally may develop late-onset proximal myopathy. The paralytic attacks are characterized by reversible flaccid paralysis usually leading to paraparesis or tetraparesis but typically sparing the respiratory muscles and heart. The onset, duration, and severity of attacks, with the associated triggers, are similar to those in individuals with ATS. Weakness is improved with oral potassium ingestion. The cardiac and dysmorphic features of ATS are, however, absent in individuals with hypokalemic periodic paralysis. Molecular testing identifies pathogenic variants in *CACNA1S* or *SCN4A* in approximately 80% of affected individuals after secondary causes such as thyrotoxicosis, diuretic use, and renal (e.g., hyperaldosteronism, distal tubular acidosis) or gastrointestinal (e.g., vomiting, diarrheal illness) causes have been ruled out. Inheritance is autosomal dominant.

**Hyperkalemic periodic paralysis** is characterized by episodes of flaccid paralysis associated with normal or elevated ictal serum potassium concentrations (>5.0 mmol/L) and aggravated by potassium ingestion. Onset is in the first decade; episodes are briefer than those that occur in individuals with hypokalemic periodic paralysis. Electrical myotonia is evident in 50% of affected individuals. The cardiac and dysmorphic features of ATS are absent. Molecular testing reveals pathogenic variants in *SCN4A* in approximately 80% of individuals. Inheritance is autosomal dominant. Secondary forms of hyperkalemic periodic paralysis to rule out include adrenal insufficiency, hypoaldosteronism, and adverse effects of certain medications (e.g., ACE inhibitors, spironolactone, nonsteroidal anti-inflammatory drugs).

**Thyrotoxic periodic paralysis** (OMIM 188580, 613239, 614834) is a consideration in any individual with severe weakness and marked hypokalemia. Men, particularly Asians, are affected in greater numbers; however, thyrotoxic periodic paralysis may be seen in individuals of all ethnicities. Diagnosis is established by measurement of serum thyroid-stimulating hormone (TSH), T4, and T3 concentrations. In one series a pathogenic variant in an inwardly rectifying potassium (*Kir*) channel (encoded by *KCNJ18*) was identified in approximately one third of affected individuals [Ryan et al 2010].

## Long QT Syndromes

See [Long QT Syndrome](#), a review of similar phenotypes that are genetically diverse.

## Palpitations, Syncope, or Cardiac Arrest

Syncopal episodes are often interpreted as a neurologic problem rather than arrhythmia. Physical examination and EKG should be part of the evaluation of syncope. Bidirectional ventricular tachycardia demonstrated on EKG may be seen with ATS, digitalis toxicity, and [catecholaminergic polymorphic ventricular tachycardia](#)

(CPVT). A normal resting EKG with exercise-induced polymorphic arrhythmias is a clue to CPVT. Pathogenic variants in *RYR2* or *CASQ2* are causative. Inheritance is autosomal dominant [Tristani-Firouzi & Etheridge 2010].

## Management

### Evaluations Following Initial Diagnosis

To establish the extent of disease and needs in an individual diagnosed with Andersen-Tawil syndrome (ATS), the evaluations summarized in Table 2 (if not performed as part of the evaluation that led to the diagnosis) are recommended.

**Table 2.** Recommended Evaluations Following Initial Diagnosis in Individuals with ATS

Organ System	Evaluation	Comment
<b>Cardiovascular</b>	Baseline assessment	Performed by cardiologist familiar w/LQT management
	12-lead EKG & 24-hour Holter monitor	
	Serum potassium concentrations	Performed at baseline & during attacks of weakness
<b>Neurologic</b>	Baseline assessment	Performed by neurologist familiar w/periodic paralysis
	Electrophysiologic studies incl long exercise protocol	
<b>Dental</b>	Baseline assessment for dental abnormalities assoc w/ATS	Follow up as needed
<b>Musculoskeletal</b>	Baseline assessment & to establish care w/orthopedist / spine surgeon if scoliosis identified	Follow up as needed
<b>Miscellaneous/ Other</b>	Serum TSH concentration	Verification that serum TSH concentration is w/in normal limits
	Consultation w/clinical geneticist &/or genetic counselor	

LQT = long QT; TSH = thyroid-stimulating hormone

### Treatment of Manifestations

Management of individuals with ATS requires the coordinated input of a neurologist familiar with the treatment of periodic paralysis and a cardiologist familiar with the treatment of cardiac arrhythmias. To date, no randomized clinical therapeutic trials have been conducted on ATS.

Management of attacks of episodic weakness depends on the associated serum potassium concentration:

- If the serum potassium concentration is low (<3.0 mmol/L), administer oral potassium (20-30 mEq/L) every 15-30 minutes (not to exceed 200 mEq in a 12-hour period) until the serum concentration normalizes often shortens the attack. As dysphagia is almost never a problem during attacks of paralysis, oral potassium replacement is the safest route. If intravenous potassium replacement is needed, a 5% mannitol solution instead of a saline or glucose solution (both of which may exacerbate weakness) is recommended. Close monitoring of serum potassium concentrations and EKG is necessary during potassium replacement therapy in an emergency setting to avoid secondary hyperkalemia.
- Whether a relative drop in serum potassium within the normal range causes episodic paralysis is not clear. If such cases are suspected, affected individuals can work with their physician to devise an individual potassium replacement regimen, with a goal of maintaining serum potassium levels in the high range of normal.



- Attacks of weakness when serum potassium concentration is high usually resolve within 60 minutes. Episodes may be shortened by ingesting carbohydrates or continuing mild exercise. Intravenous calcium gluconate is rarely necessary for management in an individual seen in an emergency setting.

Vasovagal syncope in individuals with ATS mandates a careful cardiology assessment [Airey et al 2009].

## Prevention of Primary Manifestations

Prophylactic treatment aimed at reduction of attack frequency and severity can be achieved, as in other forms of periodic paralysis, with the following:

- Lifestyle and dietary modification to avoid known triggers
- Use of carbonic anhydrase inhibitors (acetazolamide: adults 125-1,000 mg daily and children 5-10 mg/kg/day divided 1-2x/day or dichlorphenamide 50-200 mg/1-2x/day). Use of potassium-sparing diuretic should be individualized based on patient needs.
- Daily use of slow-release potassium supplements, which may also be helpful in controlling attack rates in individuals prone to hypokalemia. Elevating the serum potassium concentration (>4 mEq/L) has the added benefit of narrowing the QT interval, thus reducing the risk of LQT-associated arrhythmias.
- An implantable cardioverter-defibrillator in individuals with tachycardia-induced syncope [Chun et al 2004]
- Empiric treatment with flecainide [Bökenkamp et al 2007, Fox et al 2008, Pellizzón et al 2008] should be considered for significant, frequent ventricular arrhythmias in the setting of reduced left ventricular function [Tristani-Firouzi & Etheridge 2010]. A prospective open label study in ten individuals with ATS and a confirmed *KCNJ2* pathogenic variant tested the effect of flecainide, a type 1c antiarrhythmic, for the prevention of cardiac arrhythmias [Miyamoto et al 2015]. Outcomes included a 24-hour Holter monitor before and after treatment and a treadmill exercise test. Flecainide was found to significantly reduce the number of ventricular arrhythmias seen on Holter monitor and to suppress exercise-induced ventricular arrhythmias. Individuals were then followed for a mean of 23 months and no syncope or cardiac arrest was documented. Other case studies have reported beneficial effects with flecainide [Statland et al 2018]. A recent study showed that flecainide suppresses arrhythmogenicity through  $\text{Na}^+/\text{Ca}^{2+}$  exchanger flux in induced pluripotent stem cells derived from patients with ATS [Kuroda et al 2017]. Thus, flecainide may reduce cardiac arrhythmias in ATS.

## Prevention of Secondary Complications

Cardiologists should be aware that some antiarrhythmic drugs (e.g., lidocaine, mexiletine, propafenone, quinidine), particularly Class I drugs, may paradoxically exacerbate the neuromuscular symptoms and should be used cautiously in individuals with ATS.

Although **malignant hyperthermia** has not been reported in ATS, appropriate anesthetic precautions should be undertaken, as with individuals with other forms of periodic paralysis.

## Surveillance

For asymptomatic individuals with a *KCNJ2* pathogenic variant, annual screening including a 12-lead EKG and 24-hour Holter monitoring is desirable, followed by referral to a cardiologist if abnormalities are identified.

## Agents/Circumstances to Avoid

Affected individuals should avoid medications known to prolong QT intervals. See [CredibleMeds®](#) for a complete and updated list (free registration required).

Salbutamol inhalers, which may be used in the treatment of primary hyperkalemic periodic paralysis, should be avoided because of the potential for exacerbation of cardiac arrhythmias.

Thiazide and other potassium-wasting diuretics may provoke drug-induced hypokalemia and could aggravate the QT interval prolongation.

## Evaluation of Relatives at Risk

It is appropriate to evaluate relatives at risk in order to identify as early as possible those who would benefit from initiation of treatment and preventive measures:

- If the pathogenic variant in the family is known, molecular genetic testing can be used to clarify the genetic status of at-risk relatives.
- If the pathogenic variant in the family is not known, detailed neurologic and cardiologic evaluation, 12-lead EKG, and 24-hour Holter monitoring can be used to clarify the disease status of at-risk relatives.

See Genetic Counseling for issues related to testing of at-risk relatives for genetic counseling purposes.

## Pregnancy Management

The rarity of ATS and the paucity of reports pertaining to pregnancy in women with ATS make an evidence-based approach to pregnancy management difficult to formulate. One case study reported an uneventful pregnancy, with increased episodes of weakness but reduced ventricular ectopy compared to the pre-pregnancy period [Subbiah et al 2008]. However, as data are limited, a multidisciplinary approach to individual care and anticipation of increased risk (as can be seen in those with long QT syndrome) seems reasonable.

## Therapies Under Investigation

Search [ClinicalTrials.gov](https://clinicaltrials.gov) in the US and [EU Clinical Trials Register](https://clinicaltrialsregister.eu) in Europe for information on clinical studies for a wide range of diseases and conditions. Note: There may not be clinical trials for this disorder.

## Genetic Counseling

*Genetic counseling is the process of providing individuals and families with information on the nature, mode(s) of inheritance, and implications of genetic disorders to help them make informed medical and personal decisions. The following section deals with genetic risk assessment and the use of family history and genetic testing to clarify genetic status for family members; it is not meant to address all personal, cultural, or ethical issues that may arise or to substitute for consultation with a genetics professional. —ED.*

## Mode of Inheritance

Andersen-Tawil syndrome (ATS) is inherited in an autosomal dominant manner.

## Risk to Family Members

### Parents of a proband

- At least 50% of individuals diagnosed with ATS have an affected parent.
- A proband with ATS may have the disorder as the result of a *de novo* *KCNJ2* pathogenic variant. The proportion of cases caused by a *de novo* pathogenic variant in *KCNJ2* may be as high as 50%.
- Recommendations for the evaluation of parents of a proband with an apparent *de novo* pathogenic variant include: a detailed neurologic and cardiologic evaluation, 12-lead EKG, 24-hour Holter monitoring, and molecular genetic testing for the *KCNJ2* pathogenic variant identified in the proband.

- The family history of some individuals diagnosed with ATS may appear to be negative because of failure to recognize the disorder in family members, early death of the parent not attributed to the disease, or reduced penetrance. Therefore, an apparently negative family history cannot be confirmed unless appropriate neurologic and cardiologic evaluations and/or molecular genetic testing has been performed on the parents of the proband.

**Sibs of a proband.** The risk to the sibs of the proband depends on the genetic status of the proband's parents:

- If a parent of the proband is affected and/or has the *KCNJ2* pathogenic variant identified in the proband, the risk to the sibs of inheriting the pathogenic variant is 50%.
- If the proband has a known ATS-related pathogenic variant that cannot be detected in the leukocyte DNA of either parent, the recurrence risk to sibs is slightly greater than that of the general population because of the possibility of parental germline mosaicism [Hasegawa et al 2015].
- If the parents have not been tested for the *KCNJ2* pathogenic variant but are clinically unaffected, the risk to the sibs of a proband appears to be low. However, sibs of a proband with clinically unaffected parents are still presumed to be at increased risk for ATS because of the possibility of reduced penetrance in a heterozygous parent or the possibility of parental germline mosaicism [Hasegawa et al 2015].

**Offspring of a proband.** Each child of an individual with ATS has a 50% chance of inheriting the *KCNJ2* pathogenic variant.

**Other family members.** The risk to other family members depends on the status of the proband's parents: if a parent is affected and/or heterozygous for the *KCNJ2* pathogenic variant identified in the proband, his or her family members are at risk.

## Related Genetic Counseling Issues

See Management, Evaluation of Relatives at Risk for information on evaluating at-risk relatives for the purpose of early diagnosis and treatment.

**Considerations in families with an apparent *de novo* pathogenic variant.** When neither parent of a proband with ATS has the pathogenic variant or clinical evidence of the disorder, the *KCNJ2* pathogenic variant is likely *de novo*. However, possible non-medical explanations including alternate paternity or maternity (e.g., with assisted reproduction) or undisclosed adoption could also be explored.

### Family planning

- The optimal time for determination of genetic risk and discussion of the availability of prenatal/preimplantation genetic testing is before pregnancy.
- It is appropriate to offer genetic counseling (including discussion of potential risks to offspring and reproductive options) to young adults who are affected or at risk.

**DNA banking.** Because it is likely that testing methodology and our understanding of genes, allelic variants, and diseases will improve in the future, consideration should be given to banking DNA from probands in whom a molecular diagnosis has not been confirmed (i.e., the causative genetic alteration/s are unknown).

## Prenatal Testing and Preimplantation Genetic Testing

Once the *KCNJ2* pathogenic variant has been identified in an affected family member, prenatal testing for a pregnancy at increased risk and preimplantation genetic testing for ATS are possible.

Differences in perspective may exist among medical professionals and within families regarding the use of prenatal testing. While most centers would consider use of prenatal testing to be a personal decision, discussion of these issues may be helpful.

## Resources

GeneReviews staff has selected the following disease-specific and/or umbrella support organizations and/or registries for the benefit of individuals with this disorder and their families. GeneReviews is not responsible for the information provided by other organizations. For information on selection criteria, click [here](#).

- **National Library of Medicine Genetics Home Reference**  
[Andersen-Tawil syndrome](#)
- **Periodic Paralysis International**  
Canada  
[www.hkpp.org](http://www.hkpp.org)
- **Muscular Dystrophy Association (MDA) - USA**  
**Phone:** 833-275-6321  
[www.mda.org](http://www.mda.org)
- **Periodic Paralysis Association (PPA)**  
[www.periodicparalysis.org](http://www.periodicparalysis.org)
- **Sudden Arrhythmia Death Syndromes (SADS) Foundation**  
**Phone:** 801-948-0654  
[www.sads.org](http://www.sads.org)
- **International Long QT Syndrome Registry**  
Heart Research Follow-Up Program  
**Phone:** 585-276-0016  
**Fax:** 585-273-5283  
**Email:** [heartajm@heart.rochester.edu](mailto:heartajm@heart.rochester.edu)

## Molecular Genetics

Information in the Molecular Genetics and OMIM tables may differ from that elsewhere in the GeneReview: tables may contain more recent information. —ED.

**Table A.** Andersen-Tawil Syndrome: Genes and Databases

Gene	Chromosome Locus	Protein	Locus-Specific Databases	HGMD	ClinVar
<a href="#">KCNJ2</a>	17q24.3	Inward rectifier potassium channel 2	<a href="#">KCNJ2 database</a> <a href="#">KCNJ2 @ ZAC-GGM</a>	<a href="#">KCNJ2</a>	<a href="#">KCNJ2</a>
<a href="#">KCNJ5</a>	11q24.3	G protein-activated inward rectifier potassium channel 4	<a href="#">KCNJ5 database</a>	<a href="#">KCNJ5</a>	<a href="#">KCNJ5</a>

Data are compiled from the following standard references: gene from [HGNC](#); chromosome locus from [OMIM](#); protein from [UniProt](#). For a description of databases (Locus Specific, HGMD, ClinVar) to which links are provided, click [here](#).

**Table B.** OMIM Entries for Andersen-Tawil Syndrome ([View All in OMIM](#))

<a href="#">170390</a>	ANDERSEN CARDIODYSRHYTHMIC PERIODIC PARALYSIS
<a href="#">600681</a>	POTASSIUM CHANNEL, INWARDLY RECTIFYING, SUBFAMILY J, MEMBER 2; <a href="#">KCNJ2</a>
<a href="#">600734</a>	POTASSIUM CHANNEL, INWARDLY RECTIFYING, SUBFAMILY J, MEMBER 5; <a href="#">KCNJ5</a>

### ***KCNJ2***

**Gene structure.** *KCNJ2* has two exons spanning 5.4 kb. For a detailed summary of gene and protein information, see Table A, **Gene**.

**Pathogenic variants.** See Table A, **Locus-Specific Databases** and **HGMD**. The p.Arg218Trp pathogenic variant is considered a potential mutational hot spot [Davies et al 2005]. The majority of pathogenic variants in *KCNJ2* are missense changes. A small number of in-frame deletions and a duplication have also been reported.

**Table 3.** *KCNJ2* Pathogenic Variants Discussed in This *GeneReview*

DNA Nucleotide Change	Predicted Protein Change	Reference Sequences
c.199C>T	p.Arg67Trp <sup>1</sup>	NM_000891.2 NP_000882.1
c.271_282del12	p.Ala91_Leu94del <sup>1</sup>	
c.652C>T	p.Arg218Trp <sup>2</sup>	
c.665T>C	p.Leu222Ser <sup>2</sup>	
c.899G>A	p.Gly300Asp <sup>2</sup>	
c.953A>G	p.Asn318Ser <sup>1</sup>	
c.966G>C	p.Trp322Cys <sup>1</sup>	

Variants listed in the table have been provided by the authors. *GeneReviews* staff have not independently verified the classification of variants.

*GeneReviews* follows the standard naming conventions of the Human Genome Variation Society ([varnomen.hgvs.org](http://varnomen.hgvs.org)). See [Quick Reference](#) for an explanation of nomenclature.

1. See Genotype-Phenotype Correlations.

2. See Clinical Description.

**Normal gene product.** *KCNJ2* encodes the inward rectifier potassium channel 2 protein (Kir2.1), with 427 amino acid residues and 48-kd molecular weight. Kir2.1 is expressed primarily in skeletal muscle, heart, and brain. Kir2.1 is involved in setting and stabilizing the resting membrane potential in skeletal and cardiac muscle and has a major role in the terminal repolarization phase of the cardiac action potential [Plaster et al 2001, Tristani-Firouzi et al 2002].

**Abnormal gene product.** Pathogenic variants in *KCNJ2* cause dominant-negative suppression of Kir2.1 current [Plaster et al 2001, Tristani-Firouzi et al 2002, Lange et al 2003, Donaldson et al 2004, Davies et al 2005, Ballester et al 2006, Barajas-Martinez et al 2011, Marrus et al 2011] and affect channel-PIP<sub>2</sub> interactions [Donaldson et al 2003]. Several pathogenic variants affect trafficking of the mutant channel to the cell surface for reasons that are not clear [Ballester et al 2006]. One study identified loss of an endoplasmic reticulum export motif [Doi et al 2011]. The majority traffic normally to the cell surface but fail to conduct normally [Bendahhou et al 2003]. Phosphatidylinositol 4,5 bisphosphate (PIP<sub>2</sub>) is an important regulator of Kir2.1 channel function; many *KCNJ2* pathogenic variants alter PIP<sub>2</sub> binding [Lopes et al 2002, Donaldson et al 2003].

Flaccid paralysis results from failure to propagate action potentials in the muscle membrane as a result of sustained membrane depolarization [Cannon 2002]. The modestly prolonged QT interval and ventricular arrhythmias are caused by impaired cardiac ventricular repolarization; the reduced inward rectifying potassium current results in distinct T-U wave morphology [Tristani-Firouzi et al 2001, Zhang et al 2005].

While the role of Kir2.1 in skeletal development remains to be clarified, consistent craniofacial, dental, and skeletal anomalies are present [Yoon et al 2006a].

Targeted disruption of Kir2.1 in a knockout mouse is fatal, with complete cleft of the secondary palate [Zaritsky et al 2000].

## **KCNJ5**

**Pathogenic variants.** One individual with clinical criteria of ATS and a novel pathogenic variant in *KCNJ5* (p.Gly387Arg) has been described. The proband had periodic paralysis and ventricular arrhythmias, with a family history of ventricular arrhythmias on his father's side. A review of 21 individuals in a Japanese cohort (in whom ATS was suspected but a *KCNJ2* pathogenic variant was not found) identified one additional individual with a novel variant in *KCNJ5* (p.Thr158Ala) [Kokunai et al 2014]. The ultimate frequency of *KCNJ5* pathogenic variants in individuals who meet clinical criteria for ATS but do not have a *KCNJ2* variant remains to be determined.

**Table 4.** *KCNJ5* Pathogenic Variants Discussed in This *GeneReview*

DNA Nucleotide Change	Predicted Protein Change	Reference Sequences
c.472A>G	p.Thr158Ala <sup>1</sup>	NM_000890.3
c.1159G>C	p.Gly387Arg <sup>1</sup>	NP_000881.3

Variants listed in the table have been provided by the authors. *GeneReviews* staff have not independently verified the classification of variants.

*GeneReviews* follows the standard naming conventions of the Human Genome Variation Society ([varnomen.hgvs.org](http://varnomen.hgvs.org)). See [Quick Reference](#) for an explanation of nomenclature.

1. See Table 1.

**Normal gene product.** *KCNJ5* codes a 419-amino-acid G protein-activated inwardly rectifying potassium channel protein 4 (Kir3.4). Expression studies show that *KCNJ5* is expressed in cardiac and skeletal muscle.

**Abnormal gene product.** Functional studies on the p.Gly387Arg pathogenic variant in *KCNJ5* also demonstrated a dominant-negative effect on Kir2.1 function [Kokunai et al 2014].

## References

### Literature Cited

- Ai T, Fujiwara Y, Tsuji K, Otani H, Nakano S, Kubo Y, Horie M. Novel *KCNJ2* mutation in familial periodic paralysis with ventricular dysrhythmia. *Circulation*. 2002;105:2592–4. PubMed PMID: 12045162.
- Airey KJ, Etheridge SP, Tawil R, Tristani-Firouzi M. Resuscitated sudden cardiac death in Andersen-Tawil syndrome. *Heart Rhythm*. 2009;6:1814–7. PubMed PMID: 19959136.
- Andelfinger G, Tapper AR, Welch RC, Vanoye CG, George AL Jr, Benson DW. *KCNJ2* mutation results in Andersen syndrome with sex-specific cardiac and skeletal muscle phenotypes. *Am J Hum Genet*. 2002;71:663–8. PubMed PMID: 12148092.
- Andersen ED, Krasilnikoff PA, Overvad H. Intermittent muscular weakness, extrasystoles, and multiple developmental anomalies. A new syndrome? *Acta Paediatr Scand*. 1971;60:559–64. PubMed PMID: 4106724.
- Ballester LY, Benson DW, Wong B, Law IH, Mathews KD, Vanoye CG, George AL Jr. Trafficking-competent and trafficking-defective *KCNJ2* mutations in Andersen syndrome. *Hum Mutat*. 2006;27:388. PubMed PMID: 16541386.
- Barajas-Martinez H, Hu D, Ontiveros G, Caceres G, Desai M, Burashnikov E, Scaglione J, Antzelevitch C. Biophysical and molecular characterization of a novel de novo *KCNJ2* mutation associated with Andersen-Tawil syndrome and catecholaminergic polymorphic ventricular tachycardia mimicry. *Circ Cardiovasc Genet*. 2011;4:51–7. PubMed PMID: 21148745.
- Bendahhou S, Donaldson MR, Plaster NM, Tristani-Firouzi M, Fu YH, Ptáček LJ. Defective potassium channel Kir2.1 trafficking underlies Andersen-Tawil syndrome. *J Biol Chem*. 2003;278:51779–85. PubMed PMID: 14522976.



- Bökenkamp R, Wilde AA, Schalij MJ, Blom NA. Flecainide for recurrent malignant ventricular arrhythmias in two siblings with Andersen-Tawil syndrome. *Heart Rhythm*. 2007;4:508–11. PubMed PMID: 17399642.
- Cannon SC. An expanding view for the molecular basis of familial periodic paralysis. *Neuromuscul Disord*. 2002;12:533–43. PubMed PMID: 12117476.
- Chun TU, Epstein MR, Dick M 2nd, Andelfinger G, Ballester L, Vanoye CG, George AL Jr, Benson DW. Polymorphic ventricular tachycardia and KCNJ2 mutations. *Heart Rhythm*. 2004;1:235–41. PubMed PMID: 15851159.
- Davies NP, Imbrici P, Fialho D, Herd C, Bilslund LG, Weber A, Mueller R, Hilton-Jones D, Ealing J, Boothman BR, Giunti P, Parsons LM, Thomas M, Manzur AY, Jurkat-Rott K, Lehmann-Horn F, Chinnery PF, Rose M, Kullmann DM, Hanna MG. Andersen-Tawil syndrome: new potassium channel mutations and possible phenotypic variation. *Neurology*. 2005;65:1083–9. PubMed PMID: 16217063.
- Delannoy E, Sacher F, Maury P, Mabo P, Mansourati J, Magnin I, Camous JP, Tournant G, Rendu E, Kyndt F, Haïssaguerre M, Béziau S, Guyomarch B, Le Marec H, Fressart V, Denjoy I, Probst V. Cardiac characteristics and long-term outcome in Andersen-Tawil syndrome patients related to KCNJ2 mutation. *Europace*. 2013;15:1805–11. PubMed PMID: 23867365.
- Doi T, Makiyama T, Morimoto T, Haruna Y, Tsuji K, Ohno S, Akao M, Takahashi Y, Kimura T, Horie M. A novel KCNJ2 nonsense mutation, S369X, impedes trafficking and causes a limited form of Andersen-Tawil syndrome. *Circ Cardiovasc Genet*. 2011;4:253–60. PubMed PMID: 21493816.
- Donaldson MR, Jensen JL, Tristani-Firouzi M, Tawil R, Bendahhou S, Suarez WA, Cobo AM, Poza JJ, Behr E, Wagstaff J, Szepietowski P, Pereira S, Mozaffar T, Escolar DM, Fu YH, Ptáček LJ. PIP2 binding residues of Kir2.1 are common targets of mutations causing Andersen syndrome. *Neurology*. 2003;60:1811–6. PubMed PMID: 12796536.
- Donaldson MR, Yoon G, Fu YH, Ptacek LJ. Andersen-Tawil syndrome: a model of clinical variability, pleiotropy, and genetic heterogeneity. *Ann Med*. 2004;36 Suppl 1:92–7. PubMed PMID: 15176430.
- Fernlund E, Lundin C, Hertervig E, Kongstad O, Alders M, Platonov P. Novel mutation in the KCNJ2 gene is associated with a malignant arrhythmic phenotype of Andersen-Tawil syndrome. *Ann Noninvasive Electrocardiol*. 2013;18:471–8. PubMed PMID: 24047492.
- Fournier E, Arzel M, Sternberg D, Vicart S, Laforet P, Eymard B, Willer JC, Tabti N, Fontaine B. Electromyography guides toward subgroups of mutations in muscle channelopathies. *Ann Neurol*. 2004;56:650–61. PubMed PMID: 15389891.
- Fox DJ, Klein GJ, Hahn A, Skanes AC, Gula LJ, Yee RK, Subbiah RN, Krahn AD. Reduction of complex ventricular ectopy and improvement in exercise capacity with flecainide therapy in Andersen-Tawil syndrome. *Europace*. 2008;10:1006–8. PubMed PMID: 18621769.
- Haruna Y, Kobori A, Makiyama T, Yoshida H, Akao M, Doi T, Tsuji K, Ono S, Nishio Y, Shimizu W, Inoue T, Murakami T, Tsuboi N, Yamanouchi H, Ushinohama H, Nakamura Y, Yoshinaga M, Horigome H, Aizawa Y, Kita T, Horie M. Genotype-phenotype correlations of KCNJ2 mutations in Japanese patients with Andersen-Tawil syndrome. *Hum Mutat*. 2007;28:208. PubMed PMID: 17221872.
- Hasegawa K, Ohno S, Kimura H, Itoh H, Makiyama T, Yoshida Y, Horie M. Mosaic KCNJ2 mutation in Andersen-Tawil syndrome: targeted deep sequencing is useful for the detection of mosaicism. *Clin Genet*. 2015;87:279–83. PubMed PMID: 24635491.
- Horga A, Raja Rayan DL, Matthews E, Sud R, Fialho D, Durran SC, Burge JA, Portaro S, Davis MB, Haworth A, Hanna MG. Prevalence study of genetically defined skeletal muscle channelopathies in England. *Neurology*. 2013;80:1472–5. PubMed PMID: 23516313.

- Hosaka Y, Hanawa H, Washizuka T, Chinushi M, Yamashita F, Yoshida T, Komura S, Watanabe H, Aizawa Y. Function, subcellular localization and assembly of a novel mutation of KCNJ2 in Andersen's syndrome. *J Mol Cell Cardiol.* 2003;35:409–15. PubMed PMID: 12689820.
- Katz JS, Wolfe GI, Iannaccone S, Bryan WW, Barohn RJ. The exercise test in Andersen syndrome. *Arch Neurol.* 1999;56:352–6. PubMed PMID: 10190827.
- Kim NR, Jang J, Jean GW, Cho E, Sin JB. Identification of the KCNJ2 mutation in a Korean family with Andersen-Tawil syndrome and developmental delay. *Ann Clin Lab Sci.* 2016;46:110–3. PubMed PMID: 26927354.
- Kimura H, Zhou J, Kawamura M, Itoh H, Mizusawa Y, Ding WG, Wu J, Ohno S, Makiyama T, Miyamoto A, Naiki N, Wang Q, Xie Y, Suzuki T, Tateno S, Nakamura Y, Zang WJ, Ito M, Matsuura H, Horie M. Phenotype variability in patients carrying KCNJ2 mutations. *Circ Cardiovasc Genet.* 2012;5:344–53. PubMed PMID: 22589293.
- Kokunai Y, Nakata T, Furuta M, Sakata S, Kimura H, Aiba T, Yoshinaga M, Osaki Y, Nakamori M, Itoh H, Sato T, Kubota T, Kadota K, Shindo K, Mochizuki H, Shimizu W, Horie M, Okamura Y, Ohno K, Takahashi MP. A Kir3.4 mutation causes Andersen-Tawil syndrome by an inhibitory effect on Kir2.1. *Neurology.* 2014;82:1058–64. PubMed PMID: 24574546.
- Koppikar S, Barbosa-Barros R, Baranchuk A. A practical approach to the investigation of an rSr' pattern in leads V1-V2. *Can J Cardiol.* 2015;31:1493–6. PubMed PMID: 26143139.
- Krych M, Biernacka EK, Poninska J, Kukla P, Filipecki A, Gajda R, Hasdemir C, Antzelevitch C, Kosiec A, Malgorzata S, Ploski R, Trusz-Gluza M, Mizia-Stec K, Hoffman P. Andersen-Tawil syndrome: Clinical presentation and predictors of symptomatic arrhythmias - possible role of polymorphisms K897T in KCNH2 and H558R in SCN5A gene. *Journal of Cardiology.* 2017;70:504–10. PubMed PMID: 28336205.
- Kuntzer T, Flocard F, Vial C, Kohler A, Magistris M, Labarre-Vila A, Gonnaud PM, Ochsner F, Soichot P, Chan V, Monnier G. Exercise test in muscle channelopathies and other muscle disorders. *Muscle Nerve.* 2000;23:1089–94. PubMed PMID: 10883004.
- Kuroda Y, Yuasa S, Watanabe Y, Ito S, Egashira T, Seki T, Hattori T, Ohno S, Kodaira M, Suzuki T, Hashimoto H, Okata S, Tanaka A, Aizawa Y, Murata M, Aiba T, Makita N, Furukawa T, Shimizu W, Kodama I, Ogawa S, Kokubun N, Horigome H, Horie M, Kamiya K, Fukuda K. Flecainide ameliorates arrhythmogenicity through NCX flux in Andersen-Tawil syndrome-iPS cell-derived cardiomyocytes. *Biochem Biophys Rep.* 2017;9:245–56. PubMed PMID: 28956012.
- Lange PS, Er F, Gassanov N, Hoppe UC. Andersen mutations of KCNJ2 suppress the native inward rectifier current IK1 in a dominant-negative fashion. *Cardiovasc Res.* 2003;59:321–7. PubMed PMID: 12909315.
- Lestner JM, Ellis R, Canham N. Delineating the 17q24.2-q24.3 microdeletion syndrome phenotype. *Eur J Med Genet.* 2012;55:700–4. PubMed PMID: 22982078.
- Limberg MM, Zumhagen S, Netter MF, Coffey AJ, Grace A, Rogers J, Böckelmann D, Rinné S, Stallmeyer B, Decher N, Schulze-Bahr E. Non dominant-negative KCNJ2 gene mutations leading to Andersen-Tawil syndrome with an isolated cardiac phenotype. *Basic Res Cardiol.* 2013;108:353. PubMed PMID: 23644778.
- Lopes CM, Zhang H, Rohacs T, Jin T, Yang J, Logothetis DE. Alterations in conserved Kir channel-PIP2 interactions underlie channelopathies. *Neuron.* 2002;34:933–44. PubMed PMID: 12086641.
- Marquis-Nicholson R, Prosser DO, Love JM, Zhang L, Hayes I, George AM, Crawford JR, Skinner JR, Love DR. Array comparative genomic hybridization identifies a heterozygous deletion of the entire KCNJ2 gene as a cause of sudden cardiac death. *Circ Cardiovasc Genet.* 2014;7:17–22. PubMed PMID: 24395924.
- Marrus SB, Cuculich PS, Wang W, Nerbonne JM. Characterization of a novel, dominant negative KCNJ2 mutation associated with Andersen-Tawil syndrome. *Channels (Austin).* 2011;5:500–9. PubMed PMID: 22186697.

- Miyamoto K, Aiba T, Kimura H, Hayashi H, Ohno S, Yasuoka C, Tanioka Y, Tsuchiya T, Yoshida Y, Hayashi H, Tsuboi I, Nakajima I, Ishibashi K, Okamura H, Noda T, Ishihara M, Anzai T, Yasuda S, Miyamoto Y, Kamakura S, Kusano K, Ogawa H, Horie M, Shimizu W. Efficacy and safety of flecainide for ventricular arrhythmias in patients with Andersen-Tawil syndrome with KCNJ2 mutations. *Heart Rhythm*. 2015;12:596–603. PubMed PMID: 25496985.
- Pellizzón OA, Kalaizich L, Ptáček LJ, Tristani-Firouzi M, Gonzalez MD. Flecainide suppresses bidirectional ventricular tachycardia and reverses tachycardia-induced cardiomyopathy in Andersen-Tawil syndrome. *J Cardiovasc Electrophysiol*. 2008;19:95–7. PubMed PMID: 17655675.
- Plaster NM, Tawil R, Tristani-Firouzi M, Canún S, Bendahhou S, Tsunoda A, Donaldson MR, Iannaccone ST, Brunt E, Barohn R, Clark J, Deymeer F, George AL Jr, Fish FA, Hahn A, Nitu A, Ozdemir C, Serdaroglu P, Subramony SH, Wolfe G, Fu YH, Ptáček LJ. Mutations in Kir2.1 cause the developmental and episodic electrical phenotypes of Andersen's syndrome. *Cell*. 2001;105:511–9. PubMed PMID: 11371347.
- Rezazadeh S, Guo J, Duff HJ, Ferrier RA, Gerull B. Reversible dilated cardiomyopathy caused by a high burden of ventricular arrhythmias in Andersen-Tawil syndrome. *Can J Cardiol*. 2016;32:1576.e15–e18. PubMed PMID: 27789106.
- Ryan DP, da Silva MR, Soong TW, Fontaine B, Donaldson MR, Kung AW, Jongjaroenprasert W, Liang MC, Khoo DH, Cheah JS, Ho SC, Bernstein HS, Maciel RM, Brown RH Jr, Ptáček LJ. Mutations in potassium channel Kir2.6 cause susceptibility to thyrotoxic hypokalemic periodic paralysis. *Cell*. 2010;140:88–98. PubMed PMID: 20074522.
- Sansone V, Tawil R. Management and treatment of Andersen-Tawil syndrome. *Neurotherapeutics*. 2007;4:233–7. PubMed PMID: 17395133.
- Schoonderwoerd BA, Wiesfeld AC, Wilde AA, van den Heuvel F, Van Tintelen JP, van den Berg MP, Van Veldhuisen DJ, Van Gelder IC. A family with Andersen-Tawil syndrome and dilated cardiomyopathy. *Heart Rhythm*. 2006;3:1346–50. PubMed PMID: 17074642.
- Statland JM, Fontaine B, Hanna MG, Johnson NE, Kissel JT, Sansone VA, Shieh PB, Tawil RN, Trivedi J, Cannon SC, Griggs RC. Review of the diagnosis and treatment of periodic paralysis. *Muscle and Nerve*. 2018;57:522–30. PubMed PMID: 29125635.
- Stunnenberg BC, Raaphorst J, Deenen JCW, Links TP, Wilde AA, Verbove DJ, Kamsteeg EJ, van den Wijngaard A, Faber CG, van der Wilt GJ, van Engelen BGM, Drost G, Ginjaar HB. Prevalence and mutation spectrum of skeletal muscle channelopathies in the Netherlands. *Neuromuscul Disord*. 2018;28:402–7. PubMed PMID: 29606556.
- Subbiah RN, Gula LJ, Skanes AC, Krahn AD. Andersen-Tawil syndrome: management challenges during pregnancy, labor, and delivery. *J Cardiovasc Electrophysiol*. 2008;19:987–9. PubMed PMID: 18554214.
- Tan SV, Matthews E, Barber M, Burge JA, Rajakulendran S, Fialho D, Sud R, Haworth A, Koltzenburg M, Hanna MG. Refined exercise testing can aid DNA-based diagnosis in muscle channelopathies. *Ann Neurol*. 2011;69:328–40. PubMed PMID: 21387378.
- Tawil R, Ptáček LJ, Pavlakis SG, DeVivo DC, Penn AS, Ozdemir C, Griggs RC. Andersen's syndrome: potassium-sensitive periodic paralysis, ventricular ectopy, and dysmorphic features. *Ann Neurol*. 1994;35:326–30. PubMed PMID: 8080508.
- Tristani-Firouzi M, Chen J, Mitcheson JS, Sanguinetti MC. Molecular biology of K(+) channels and their role in cardiac arrhythmias. *Am J Med*. 2001;110:50–9. PubMed PMID: 11152866.
- Tristani-Firouzi M, Etheridge SP. Kir 2.1 channelopathies: the Andersen-Tawil syndrome. *Pflugers Arch*. 2010;460:289–94. PubMed PMID: 20306271.
- Tristani-Firouzi M, Jensen JL, Donaldson MR, Sansone V, Meola G, Hahn A, Bendahhou S, Kwiecinski H, Fidzianska A, Plaster N, Fu YH, Ptáček LJ, Tawil R. Functional and clinical characterization of KCNJ2

mutations associated with LQT7 (Andersen syndrome). *J Clin Invest*. 2002;110:381–8. PubMed PMID: 12163457.

Vergult S, Dauber A, Delle Chiaie B, Van Oudenhove E, Simon M, Rihani A, Loeys B, Hirschhorn J, Pfothenauer J, Phillips JA 3rd, Mohammed S, Ogilvie C, Crolla J, Mortier G, Menten B. 17q24.2 microdeletions: a new syndromal entity with intellectual disability, truncal obesity, mood swings and hallucinations. *Eur J Hum Genet*. 2012;20:534–9. PubMed PMID: 22166941.

Yoon G, Oberoi S, Tristani-Firouzi M, Etheridge SP, Quitania L, Kramer JH, Miller BL, Fu YH, Ptáček LJ. Andersen-Tawil syndrome: prospective cohort analysis and expansion of the phenotype. *Am J Med Genet A*. 2006a;140:312–21. PubMed PMID: 16419128.

Yoon G, Quitania L, Kramer JH, Fu YH, Miller BL, Ptáček LJ. Andersen-Tawil syndrome: definition of a neurocognitive phenotype. *Neurology*. 2006b;66:1703–10. PubMed PMID: 16769944.

Zaritsky JJ, Eckman DM, Wellman GC, Nelson MT, Schwarz TL. Targeted disruption of Kir2.1 and Kir2.2 genes reveals the essential role of the inwardly rectifying K(+) current in K(+)-mediated vasodilation. *Circ Res*. 2000;87:160–6. PubMed PMID: 10904001.

Zhang L, Benson DW, Tristani-Firouzi M, Ptacek LJ, Tawil R, Schwartz PJ, George AL, Horie M, Andelfinger G, Snow GL, Fu YH, Ackerman MJ, Vincent GM. Electrocardiographic features in Andersen-Tawil syndrome patients with KCNJ2 mutations: characteristic T-U-wave patterns predict the KCNJ2 genotype. *Circulation*. 2005;111:2720–6. PubMed PMID: 15911703.

## Chapter Notes

### Acknowledgments

The authors are funded in part by the Consortium for Clinical Investigation of Neurological Channelopathies (CINCH) supported by NIH 8 U54 NS59065 (NINDS/ORD).

### Author History

Jeffrey M Statland, MD (2013-present)

Rabi Tawil, MD (2004-present)

Aravindhan Veerapandiyam, MBBS (2018-present)

Shannon L Venance, MD, PhD; University of Western Ontario (2004-2018)

### Revision History

- 7 June 2018 (sw) Comprehensive update posted live
- 3 September 2015 (rt) Revision: Treatment of Manifestations
- 6 August 2015 (me) Comprehensive update posted live
- 3 January 2013 (me) Comprehensive update posted live
- 13 May 2010 (me) Comprehensive update posted live
- 19 March 2007 (me) Comprehensive update posted live
- 27 April 2005 (cd) Revision: prenatal diagnosis available
- 22 November 2004 (me) Review posted live
- 1 June 2004 (rt) Original submission

## License

GeneReviews® chapters are owned by the University of Washington. Permission is hereby granted to reproduce, distribute, and translate copies of content materials for noncommercial research purposes only, provided that (i) credit for

source (<http://www.genereviews.org/>) and copyright (© 1993-2024 University of Washington) are included with each copy; (ii) a link to the original material is provided whenever the material is published elsewhere on the Web; and (iii) reproducers, distributors, and/or translators comply with the [GeneReviews® Copyright Notice and Usage Disclaimer](#). No further modifications are allowed. For clarity, excerpts of GeneReviews chapters for use in lab reports and clinic notes are a permitted use.

For more information, see the [GeneReviews® Copyright Notice and Usage Disclaimer](#).

For questions regarding permissions or whether a specified use is allowed, contact: [admasst@uw.edu](mailto:admasst@uw.edu).